{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:18:49Z","timestamp":1790752729593,"version":"4.1.0"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["NRF-2014R1A1A2059179"],"award-info":[{"award-number":["NRF-2014R1A1A2059179"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["NRF-2022R1F1A1074517"],"award-info":[{"award-number":["NRF-2022R1F1A1074517"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["NRF-2016R1A5A2012284"],"award-info":[{"award-number":["NRF-2016R1A5A2012284"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["NRF-2017M3A9G2077568"],"award-info":[{"award-number":["NRF-2017M3A9G2077568"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002641","name":"Konkuk University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002641","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.neuropharm.2022.109234","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T06:04:54Z","timestamp":1661925894000},"page":"109234","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Agmatine relieves behavioral impairments in Fragile X mice model"],"prefix":"10.1016","volume":"219","author":[{"given":"Se Jin","family":"Jeon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyoung","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Jung","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edson Luck","family":"Gonzales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhyeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Jin","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Hoon","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan Young","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2022.109234_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.22227","article-title":"Agmatine protects against sodium valproate-induced hepatic injury in mice via modulation of nuclear factor-kappaB\/inducible nitric oxide synthetase pathway","volume":"32","author":"Ahmed","year":"2018","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"10.1016\/j.neuropharm.2022.109234_bib2","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41467-017-01191-2","article-title":"Altered surface mGluR5 dynamics provoke synaptic NMDAR dysfunction and cognitive defects in Fmr1 knockout mice","volume":"8","author":"Aloisi","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2022.109234_bib72","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.neuron.2019.02.041","article-title":"A synaptic perspective of fragile X syndrome and autism spectrum disorders","volume":"101","author":"Bagni","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2022.109234_bib3","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1601-183X.2010.00585.x","article-title":"Male and female Fmr1 knockout mice on C57 albino background exhibit spatial learning and memory impairments","volume":"9","author":"Baker","year":"2010","journal-title":"Gene Brain Behav."},{"key":"10.1016\/j.neuropharm.2022.109234_bib4","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.tins.2004.04.009","article-title":"The mGluR theory of fragile X mental retardation","volume":"27","author":"Bear","year":"2004","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109234_bib5","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.neuron.2007.07.035","article-title":"Rapid bidirectional switching of synaptic NMDA receptors","volume":"55","author":"Bellone","year":"2007","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2022.109234_bib6","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.neuroscience.2010.05.004","article-title":"Agmatine protects against beta-amyloid25-35-induced memory impairments in the rat","volume":"169","author":"Bergin","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2022.109234_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-49078-0","article-title":"Safety and neurochemical profiles of acute and sub-chronic oral treatment with agmatine sulfate","volume":"9","author":"Bergin","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2022.109234_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s11689-016-9181-6","article-title":"Arbaclofen in fragile X syndrome: results of phase 3 trials","volume":"9","author":"Berry-Kravis","year":"2017","journal-title":"J. Neurodev. Disord."},{"key":"10.1016\/j.neuropharm.2022.109234_bib70","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/00207454.2020.1830086","article-title":"Reversal of lipopolysaccharide-induced learning and memory deficits by agmatine in mice","volume":"132","author":"Borikar","year":"2022","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109234_bib9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.neuropharm.2014.06.028","article-title":"Insights into GABAAergic system deficits in fragile X syndrome lead to clinical trials","volume":"88","author":"Braat","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109234_bib10","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.4161\/15384101.2014.989114","article-title":"The GABAA receptor is an FMRP target with therapeutic potential in fragile X syndrome","volume":"14","author":"Braat","year":"2015","journal-title":"Cell Cycle"},{"key":"10.1016\/j.neuropharm.2022.109234_bib11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.biocel.2014.05.004","article-title":"New insights into the molecular pathophysiology of fragile X syndrome and therapeutic perspectives from the animal model","volume":"53","author":"Busquets-Garcia","year":"2014","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.neuropharm.2022.109234_bib12","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3389\/fgene.2014.00239","article-title":"Dysregulated nitric oxide signaling as a candidate mechanism of fragile X syndrome and other neuropsychiatric disorders","volume":"5","author":"Colvin","year":"2014","journal-title":"Front. Genet."},{"key":"10.1016\/j.neuropharm.2022.109234_bib13","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.biopsych.2012.06.008","article-title":"Activation of 5-HT7 serotonin receptors reverses metabotropic glutamate receptor-mediated synaptic plasticity in wild-type and Fmr1 knockout mice, a model of Fragile X syndrome","volume":"72","author":"Costa","year":"2012","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109234_bib14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.tins.2007.06.003","article-title":"The GABAA receptor: a novel target for treatment of fragile X?","volume":"30","author":"D'Hulst","year":"2007","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109234_bib15","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.2147\/NDT.S113099","article-title":"Antipsychotic-associated weight gain: management strategies and impact on treatment adherence","volume":"13","author":"Dayabandara","year":"2017","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.neuropharm.2022.109234_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.nbd.2014.12.021","article-title":"Fragile X mice have robust mGluR5-dependent alterations of social behaviour in the Automated Tube Test","volume":"75","author":"de Esch","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2022.109234_bib17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.brainres.2004.07.041","article-title":"Evidence for serotonin receptor subtypes involvement in agmatine antidepressant like-effect in the mouse forced swimming test","volume":"1023","author":"Dias Elpo Zomkowski","year":"2004","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2022.109234_bib73","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3390\/cells11081325","article-title":"Towards kinase inhibitor therapies for fragile X syndrome: tweaking twists in the autism spectrum kinase signaling network","volume":"11","author":"D\u2019Incal","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.neuropharm.2022.109234_bib18","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00702-017-1836-2","article-title":"Decreased plasma agmatine levels in autistic subjects","volume":"125","author":"Esnafoglu","year":"2018","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2022.109234_bib71","doi-asserted-by":"crossref","first-page":"174928","DOI":"10.1016\/j.ejphar.2022.174928","article-title":"The memory modulatory effect of agmatine in passive avoidance task coincides with alterations of hippocampal CaMKII-alpha and ERK signaling in mice","volume":"923","author":"Farokhi","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109234_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.104779","article-title":"FMRP regulates presynaptic localization of neuronal voltage gated calcium channels","volume":"138","author":"Ferron","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2022.109234_bib20","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2174\/1570159X13666150615221502","article-title":"Group I mGluR induced LTD of NMDAR-synaptic transmission at the schaffer collateral but not temperoammonic input to CA1","volume":"14","author":"Fitzjohn","year":"2016","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2022.109234_bib22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jpsychires.2014.07.024","article-title":"Sub-chronic agmatine treatment modulates hippocampal neuroplasticity and cell survival signaling pathways in mice","volume":"58","author":"Freitas","year":"2014","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2022.109234_bib23","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejphar.2015.11.044","article-title":"Involvement of nitric oxide in anticompulsive-like effect of agmatine on marble-burying behaviour in mice","volume":"770","author":"Gawali","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109234_bib24","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.fct.2013.10.005","article-title":"Evidence for oral agmatine sulfate safety--a 95-day high dosage pilot study with rats","volume":"62","author":"Gilad","year":"2013","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.neuropharm.2022.109234_bib25","doi-asserted-by":"crossref","first-page":"8908","DOI":"10.1523\/JNEUROSCI.0932-05.2005","article-title":"A reduced number of metabotropic glutamate subtype 5 receptors are associated with constitutive homer proteins in a mouse model of fragile X syndrome","volume":"25","author":"Giuffrida","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109234_bib26","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.neuroscience.2012.06.052","article-title":"Synaptic NMDA receptor-mediated currents in anterior piriform cortex are reduced in the adult fragile X mouse","volume":"221","author":"Gocel","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2022.109234_bib27","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s13311-015-0355-9","article-title":"Therapeutic strategies in fragile X syndrome: from bench to bedside and back","volume":"12","author":"Gross","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuropharm.2022.109234_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-34978-4","article-title":"Mavoglurant in Fragile X Syndrome: results of two open-label, extension trials in adults and adolescents","volume":"8","author":"Hagerman","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2022.109234_bib29","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2165\/00023210-200721110-00002","article-title":"Agmatine : metabolic pathway and spectrum of activity in brain","volume":"21","author":"Halaris","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2022.109234_bib30","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.neuron.2010.01.024","article-title":"Critical period plasticity is disrupted in the barrel cortex of FMR1 knockout mice","volume":"65","author":"Harlow","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2022.109234_bib31","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.neuron.2006.07.005","article-title":"Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression","volume":"51","author":"Hou","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2022.109234_bib32","doi-asserted-by":"crossref","first-page":"7746","DOI":"10.1073\/pnas.122205699","article-title":"Altered synaptic plasticity in a mouse model of fragile X mental retardation","volume":"99","author":"Huber","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2022.109234_bib33","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/npp.2011.243","article-title":"NMDA receptors, mGluR5, and endocannabinoids are involved in a cascade leading to hippocampal long-term depression","volume":"37","author":"Izumi","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109234_bib34","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/6015753","article-title":"Synaptic plasticity and excitation-inhibition balance in the dentate gyrus: insights from in vivo recordings in neuroligin-1, neuroligin-2, and collybistin knockouts","author":"Jedlicka","year":"2018","journal-title":"Neural Plast 2018"},{"key":"10.1016\/j.neuropharm.2022.109234_bib35","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.neuropharm.2017.09.014","article-title":"Maslinic acid ameliorates NMDA receptor blockade-induced schizophrenia-like behaviors in mice","volume":"126","author":"Jeon","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109234_bib36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.neuropharm.2016.09.014","article-title":"Agmatine rescues autistic behaviors in the valproic acid-induced animal model of autism","volume":"113","author":"Kim","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109234_bib37","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejphar.2015.02.033","article-title":"Chronic agmatine treatment prevents behavioral manifestations of nicotine withdrawal in mice","volume":"754","author":"Kotagale","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109234_bib38","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.neulet.2010.06.002","article-title":"Nitric oxide is involved in the regulation of marble-burying behavior","volume":"480","author":"Krass","year":"2010","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2022.109234_bib39","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1042\/BCJ20170007","article-title":"Agmatine: multifunctional arginine metabolite and magic bullet in clinical neuroscience?","volume":"474","author":"Laube","year":"2017","journal-title":"Biochem. J."},{"key":"10.1016\/j.neuropharm.2022.109234_bib40","doi-asserted-by":"crossref","first-page":"10685","DOI":"10.1523\/JNEUROSCI.2624-07.2007","article-title":"Brain-derived neurotrophic factor rescues synaptic plasticity in a mouse model of fragile X syndrome","volume":"27","author":"Lauterborn","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109234_bib41","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.neuron.2011.09.033","article-title":"Bidirectional regulation of dendritic voltage-gated potassium channels by the fragile X mental retardation protein","volume":"72","author":"Lee","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2022.109234_bib42","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/8548910","article-title":"An abnormal nitric oxide metabolism contributes to brain oxidative stress in the mouse model for the fragile X syndrome, a possible role in intellectual disability","author":"Lima-Cabello","year":"2016","journal-title":"Oxid Med Cell Longev 2016"},{"key":"10.1016\/j.neuropharm.2022.109234_bib43","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1172\/JCI118430","article-title":"Agmatine, a bioactive metabolite of arginine. Production, degradation, and functional effects in the kidney of the rat","volume":"97","author":"Lortie","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neuropharm.2022.109234_bib44","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.1007\/s12035-017-0666-4","article-title":"Increased training intensity induces proper membrane localization of actin remodeling proteins in the Hippocampus preventing cognitive deficits: implications for fragile X syndrome","volume":"55","author":"Martinez","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2022.109234_bib45","doi-asserted-by":"crossref","first-page":"6344","DOI":"10.1093\/nar\/gky267","article-title":"HITS-CLIP in various brain areas reveals new targets and new modalities of RNA binding by fragile X mental retardation protein","volume":"46","author":"Maurin","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.neuropharm.2022.109234_bib46","doi-asserted-by":"crossref","DOI":"10.1038\/srep26651","article-title":"Abnormal intrinsic dynamics of dendritic spines in a fragile X syndrome mouse model in vivo","volume":"6","author":"Nagaoka","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2022.109234_bib47","doi-asserted-by":"crossref","first-page":"15537","DOI":"10.1073\/pnas.0707484104","article-title":"Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors","volume":"104","author":"Nakamoto","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2022.109234_bib48","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.neuint.2017.05.006","article-title":"Therapeutic potential of agmatine for CNS disorders","volume":"108","author":"Neis","year":"2017","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2022.109234_bib49","doi-asserted-by":"crossref","first-page":"9929","DOI":"10.1523\/JNEUROSCI.1714-10.2010","article-title":"Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome","volume":"30","author":"Olmos-Serrano","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109234_bib50","doi-asserted-by":"crossref","first-page":"17768","DOI":"10.1073\/pnas.1012496107","article-title":"Dendritic spine instability and insensitivity to modulation by sensory experience in a mouse model of fragile X syndrome","volume":"107","author":"Pan","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2022.109234_bib51","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1196\/annals.1304.007","article-title":"Agmatine crosses the blood-brain barrier","volume":"1009","author":"Piletz","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2022.109234_bib52","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.drudis.2013.05.017","article-title":"Agmatine: clinical applications after 100 years in translation","volume":"18","author":"Piletz","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.neuropharm.2022.109234_bib53","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s12640-013-9376-5","article-title":"Putative agmatinase inhibitor for hypoxic-ischemic new born brain damage","volume":"24","author":"Piletz","year":"2013","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.neuropharm.2022.109234_bib54","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00213-013-3330-3","article-title":"Fragile X syndrome: a preclinical review on metabotropic glutamate receptor 5 (mGluR5) antagonists and drug development","volume":"231","author":"Pop","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2022.109234_bib55","first-page":"187","article-title":"Neuroprotective effects of receptor imidazoline 2 and its endogenous ligand agmatine","volume":"22","author":"Qiu","year":"2006","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.neuropharm.2022.109234_bib56","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.neuropharm.2016.12.010","article-title":"Impaired GABAergic inhibition in the hippocampus of Fmr1 knockout mice","volume":"116","author":"Sabanov","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109234_bib74","doi-asserted-by":"crossref","first-page":"E6290","DOI":"10.1073\/pnas.1610812113","article-title":"Elevated ERK\/p90 ribosomal S6 kinase activity underlies audiogenic seizure susceptibility in fragile X mice","volume":"113","author":"Sawicka","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2022.109234_bib57","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.coph.2014.11.004","article-title":"Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome","volume":"20","author":"Scharf","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109234_bib58","doi-asserted-by":"crossref","first-page":"25479","DOI":"10.1074\/jbc.M109.042663","article-title":"Fragile X mental retardation protein regulates the levels of scaffold proteins and glutamate receptors in postsynaptic densities","volume":"284","author":"Schutt","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2022.109234_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22020698","article-title":"Inhibitory neural network's impairments at hippocampal CA1 LTP in an aged transgenic mouse model of alzheimer's disease","volume":"22","author":"Seo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2022.109234_bib60","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1039\/C5MB00423C","article-title":"Fragile X mental retardation protein interactions with a G quadruplex structure in the 3'-untranslated region of NR2B mRNA","volume":"11","author":"Stefanovic","year":"2015","journal-title":"Mol. Biosyst."},{"key":"10.1016\/j.neuropharm.2022.109234_bib61","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1093\/hmg\/dds030","article-title":"Altered maturation of the primary somatosensory cortex in a mouse model of fragile X syndrome","volume":"21","author":"Till","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2022.109234_bib62","doi-asserted-by":"crossref","first-page":"9817","DOI":"10.1523\/JNEUROSCI.3038-15.2016","article-title":"Dysregulated NMDA-receptor signaling inhibits long-term depression in a mouse model of fragile X syndrome","volume":"36","author":"Toft","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109234_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2019.112068","article-title":"Reversal of ultrasonic vocalization deficits in a mouse model of Fragile X Syndrome with minocycline treatment or genetic reduction of MMP-9","volume":"372","author":"Toledo","year":"2019","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2022.109234_bib64","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.neubiorev.2011.08.006","article-title":"The pharmacological importance of agmatine in the brain","volume":"36","author":"Uzbay","year":"2012","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2022.109234_bib65","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1523\/JNEUROSCI.0646-08.2008","article-title":"Roles of calcium-stimulated adenylyl cyclase and calmodulin-dependent protein kinase IV in the regulation of FMRP by group I metabotropic glutamate receptors","volume":"28","author":"Wang","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109234_bib66","article-title":"The therapeutic effect of memantine through the stimulation of synapse formation and dendritic spine maturation in autism and fragile X syndrome","volume":"7","author":"Wei","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2022.109234_bib67","first-page":"746","article-title":"Agmatine blocked voltage-gated calcium channel in cultured rat hippocampal neurons","volume":"24","author":"Weng","year":"2003","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.neuropharm.2022.109234_bib68","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1179\/016164107X208103","article-title":"Agmatine inhibits matrix metalloproteinase-9 via endothelial nitric oxide synthase in cerebral endothelial cells","volume":"29","author":"Yang","year":"2007","journal-title":"Neurol. Res."},{"key":"10.1016\/j.neuropharm.2022.109234_bib69","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.nlm.2018.05.016","article-title":"Activation of the dopamine D1 receptor can extend long-term spatial memory persistence via PKA signaling in mice","volume":"155","author":"Zhang","year":"2018","journal-title":"Neurobiol. Learn. Mem."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822002933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822002933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:19:18Z","timestamp":1758439158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390822002933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":73,"alternative-id":["S0028390822002933"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109234","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Agmatine relieves behavioral impairments in Fragile X mice model","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109234","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109234"}}